Impact of Implementing a Real Time Frequent Admitter Risk Score (FAM-FACE-SG) on Readmission Rates
NCT02815462 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2023-04-28
Summary
In an earlier study using electronic health records (EHR), the investigators have identified nine factors to be significantly associated with FA risk. These nine predictors include Furosemide intravenous 40 milligrams or more; Admissions in the past one year; Medifund status; Frequent emergency department use; Anti-depressants treatment in past one year; Charlson comorbidity index; End Stage Renal Failure on dialysis; Subsidized ward stay and Geriatric patient. The investigators have combined these nine predictors into the FAM-FACE-SG score for FA risk (defined as 3 or more inpatient admissions in the following 12 months). The FAM-FACE-SG risk score has the advantage of being deployed in our hospital's enterprise data repository known as Electronic Health Intelligence System or eHINTs for short, on a real-time or near real-time basis. On a daily basis, data from multiple data sources are extracted, transformed and loaded onto the eHINTS system. The system can be programmed to run every midnight to provide risk scores the following morning for patients admitted the previous day.
In this trial, the intervention is to combine the FAM-FACE-SG risk score in addition to a decision making algorithm to guide referrals to various transitional care services based on needs assessment on nursing and function. The primary objective is to evaluate the impact of our intervention in improving healthcare utilization (hospital readmissions, emergency department (ED) attendances, length of stay up to 90 days post-discharge).
Conditions
- Patient Readmission
Interventions
- OTHER
-
FAMFACESG
\- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
- OTHER
-
Control
\- Usual hospital Care
- OTHER
-
FAMFACESG
\- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
- OTHER
-
FAMFACESG
* For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up. * For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC. * For mild risk patients, PNs will refer them to care coordinator.
- OTHER
-
FAMFACESG
\- For low risk patients, PNs will continue usual hospital care.
Sponsors & Collaborators
-
Singapore General Hospital
lead OTHER
Principal Investigators
-
Lian Leng Low · Singapore General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-31
- Primary Completion
- 2017-08-31
- Completion
- 2017-08-31
Countries
- Singapore
Study Locations
More Related Trials
-
User Experience of a Mobile Application
NCT04231188 ·Status: TERMINATED
-
Evaluation of Pediatric eCART Implementation
NCT06771830 ·Status: RECRUITING ·Phase: NA
-
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439645 ·Status: TERMINATED
-
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
NCT04371315 ·Status: COMPLETED
-
Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome
NCT03680924 ·Status: COMPLETED
-
Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years
NCT06417320 ·Status: RECRUITING ·Phase: PHASE4
-
The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
NCT06208332 ·Status: RECRUITING ·Phase: PHASE2
-
The Fontan Education Study: A Randomized Control Trial
NCT02831790 ·Status: COMPLETED ·Phase: NA
-
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension
NCT04489251 ·Status: UNKNOWN
-
Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit
NCT00465361 ·Status: COMPLETED ·Phase: NA
-
AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone
NCT00719147 ·Status: COMPLETED
-
Study of Initial Steroid Treatment in Young Children With Nephrotic Syndrome
NCT04536181 ·Status: WITHDRAWN ·Phase: PHASE3
-
Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome
NCT03235128 ·Status: UNKNOWN
-
Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children
NCT03649919 ·Status: WITHDRAWN
-
Thoracic MRI Imaging in Children
NCT02714933 ·Status: COMPLETED ·Phase: NA
-
Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
NCT05734794 ·Status: RECRUITING ·Phase: PHASE3
-
Microbiologic Findings of Acute Facial Palsy in Children
NCT01537952 ·Status: COMPLETED
-
miRNA in Pediatric Gastritis
NCT07300787 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
NCT04284371 ·Status: TERMINATED
-
Randomized Controlled Trial of Voice on Children With Vocal Nodules
NCT01255735 ·Status: COMPLETED
-
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
NCT06923124 ·Status: COMPLETED
-
Quantifying Effects of Treatment of Pediatric Dysphonia
NCT00237679 ·Status: TERMINATED ·Phase: NA
-
Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02414438 ·Status: COMPLETED ·Phase: NA
-
Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
NCT02752191 ·Status: COMPLETED ·Phase: PHASE4
-
Placental Lesions in Fetal Growth Restrictions
NCT04839185 ·Status: COMPLETED ·Phase: EARLY_PHASE1